Загрузка...
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant
Current landscape of treatment of castration-resistant prostate cancer (CRPC) has recently changed. Cabazitaxel, a new taxane with potential antineoplastic activity, has been approved by Food and Drug Administration (FDA) after docetaxel failure. In a phase III trial, cabazitaxel showed increased ov...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Landes Bioscience
2012
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3461806/ https://ncbi.nlm.nih.gov/pubmed/22825325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.21188 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|